Antibiotics Causing Low Total Leukocyte Count (Neutropenia)
The antibiotics most commonly associated with causing neutropenia are vancomycin, ceftriaxone, cloxacillin, ceftaroline, beta-lactams (particularly penicillins and cephalosporins), sulfamethoxazole-trimethoprim, and ticlopidine.
High-Risk Antibiotics Based on Recent Evidence
The most robust recent data comes from a 2023 retrospective cohort study of outpatient parenteral antibiotic therapy (OPAT) patients 1. This study identified specific incidence rates:
- Vancomycin: 3.9% incidence (21/541 treatment courses)
- Ceftriaxone: 2.0% incidence (10/490 treatment courses)
- Cloxacillin: 1.9% incidence (2/103 treatment courses)
Ceftaroline deserves special attention for prolonged therapy (>14 days). Multiple studies demonstrate concerning rates:
- 18% developed neutropenia with median duration of 27 days 2
- 17% incidence compared to 3.9% with other antibiotics when used >14 days 3
- Adjusted odds ratio of 3.97 for neutropenia development compared to other anti-staphylococcal agents 3
Additional Culprit Antibiotics
Other antibiotics frequently implicated in drug-induced immune neutropenia include 4:
- Beta-lactam antibiotics (as a class)
- Sulfamethoxazole-trimethoprim
- Diclofenac
- Ticlopidine
- Antithyroid drugs (propylthiouracil)
- Carbamazepine
- Clozapine
- Levamisole
Cefepime has also been reported to cause neutropenia, particularly in pediatric cystic fibrosis patients receiving prolonged treatment 5.
Mechanism and Clinical Presentation
Drug-induced immune neutropenia (DIIN) occurs when drug-dependent antibodies form against neutrophil membrane glycoproteins, causing neutrophil destruction 4. Patients typically present with:
- Fever and chills
- Infections
- Absolute neutrophil count (ANC) <1,500 cells/mm³
- Severe neutropenia defined as ANC <500 cells/mm³
Monitoring Recommendations
For vancomycin in OPAT settings: Weekly laboratory monitoring 1
For other antibiotics in OPAT: Laboratory monitoring at week 3 of therapy 1
For ceftaroline when used >7 days 2:
- Obtain complete blood count (CBC) with differential at therapy onset
- Weekly CBC thereafter
- If ANC falls below 2,500 cells/mm³: increase to twice-weekly monitoring
- Discontinue therapy if ANC ≤1,500 cells/mm³
The median time to first neutropenic episode with ceftaroline is day 17, with nadir ANC occurring around day 24 2.
Management Approach
When antibiotic-induced neutropenia is identified 1:
- Discontinue the offending antibiotic - all patients recovered neutrophil counts after discontinuation or completion
- For beta-lactams: Can safely switch to an alternate beta-lactam with a structurally different side chain (100% success rate in 9/9 cases)
- Consider granulocyte colony-stimulating factor (G-CSF) to hasten neutrophil recovery 4
- Only 9.1% of cases required hospital admission when detected through standardized outpatient monitoring 1
Critical Pitfall
The most important caveat is distinguishing between antibiotic-induced neutropenia (the antibiotic causes the low count) versus neutropenia requiring antibiotic prophylaxis (the patient already has neutropenia from chemotherapy/disease). The guidelines 6, 7 discuss using fluoroquinolones for prophylaxis in high-risk neutropenic cancer patients, but this is a completely different clinical scenario than antibiotics causing neutropenia.
No deaths were reported in the OPAT cohort when neutropenia was detected early through systematic monitoring 1, emphasizing the importance of proactive surveillance rather than reactive management.